Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

Buy-and-Bill

COVID-19

Case-Based Roundtable

Chronic Hand Eczema

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Perspectives in Dermatology

Polls

Editorial Advisory Board

Partners

Subscribe

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and is now finishing her Masters in Digital Media through Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family.

Articles

Researchers found that PsA patients prioritize fatigue, sleep issues, and uncertainty, often ranking them higher than doctors do.

Study Explores Gaps in Patient-Doctor PsA Priorities

Marie Bosslett is the assistant editor of 

 and joined the MJH Life Sciences team in October 2024. She attended Loyola University Maryland in Baltimore and earned a Bachelor of Arts in Communication with minors in marketing and writing. When she’s not writing, Marie enjoys going to concerts, reading on the beach, and spending time with friends and family.

There are numerous ways for dermatologists to get involved in initiatives from the Skin Cancer Foundation, according to Becky Kamowitz.

Expanding Collaborations in the Fight Against Skin Cancer

Patients with hidradenitis suppurativa experience knowledge gaps on effective treatments and addressing these gaps could help prevent tissue damage among patients.

Improving Hidradenitis Suppurativa Outcomes by Addressing Treatment Gaps

This innovative approach to multimodal aesthetics care was announced at IMCAS World Congress 2025.

ICYMI: Allergan Unveils AA Signature Program for Personalized Treatment

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

Authors

We had the chance to catch up with Serrao before he took the stage and he explained why dermatology clinicians should keep their eyes on bimekizumab’s data and shared opportunities for further research.

Rocco Serrao, MD Looks Ahead to Bimekizumab’s Approval

Final Thoughts: The Importance of Comparative Studies in AD

Panelists offer concluding insights and emphasize the critical role of comparative studies in advancing atopic dermatitis treatment strategies.

clinical

Video Series

Hyperhidrosis is not rare. According to the 

, approximately 385 million people worldwide live with hyperhidrosis.

In fact, they note that the amount of people living with chronic, excessive sweating is even higher than the amount of people living with other dermatologic conditions like psoriasis.

Just how common is hyperhidrosis in real-world comparisons?

The prevalence of hyperhidrosis is much higher in younger populations than in the general population, with 8.8% of individuals between the ages of 18 to 39 years old living with the condition. 

When comparing these statistics to everyday, common occurrences like hair color, the number of people with hyperhidrosis is greater than the 1% of individuals with natural red hair and 2% of individuals with natural blond hair. 

Despite how common hyperhidrosis is, it is estimated that 27% of those with the condition never receive a diagnosis.

 wants to hear from you. What percentage of the global population is estimated to have hyperhidrosis?

 to share your hyperhidrosis insights or research.

Albert. Fact check: Hyperhidrosis - International Hyperhidrosis Society: Official site. Home - International Hyperhidrosis Society. October 24, 1970. Accessed November 16, 2023. 

https://www.sweathelp.org/home/news-blog/542-fact-check-hyperhidrosis.html

Hyperhidrosis affects approximately 385 million people globally, surpassing the prevalence of other dermatologic conditions like psoriasis. It is notably more common in younger populations, with 8.8% of individuals aged 18 to 39 experiencing the condition. Comparatively, hyperhidrosis is more prevalent than natural red or blond hair, which affects 1% and 2% of the population, respectively. Despite its prevalence, 27% of those with hyperhidrosis remain undiagnosed. The article encourages engagement during Hyperhidrosis Awareness Month to share insights and research on the condition.

Click here to answer this week's poll for Hyperhidrosis Awareness Month.

Polls 

POLL: What Percent of the Global Population is Estimated to Have Hyperhidrosis?

The 2022 Annual Society of Dermatology Nurse Practitioners (SDNP) Symposium is happening this weekend, April 22 to 23, in Nashville, Tennessee at the Gaylord Opryland. This third edition of the event is in person and will feature a certification review course on April 24 and 25.

This event will have sessions on important topics such as immunology, dermatoses, hair disorders and more. It will also feature morning exercises, line dancing, and other networking opportunities. Not to mention the chance to have a headshot taken between the 2 days.

This meeting is specifically aimed at dermatology nurse practitioners (NPs) and offers them the support and knowledge they need to excel in the field. To learn more about the symposium please visit their website, 

Sdnp 2022 annual symposium. Accessed April 20, 2022. https://www.dermnp.org/sdnp-2022-annual-symposium_

The 2022 Annual Society of Dermatology Nurse Practitioners Symposium is taking place in Nashville, Tennessee, from April 22 to 23, with a certification review course on April 24 and 25. This in-person event will cover key topics such as immunology, dermatoses, and hair disorders, alongside networking activities like morning exercises and line dancing. Aimed at dermatology nurse practitioners, the symposium provides essential support and knowledge to advance in their field. Attendees can also have professional headshots taken during the event.

The Society of Dermatology Nurse Practitioners is having its annual conference this weekend, starting April 22 through 23 with a certification review course happening April 24 to 25, in Nashville, Tennessee. 

Starting Off the SDNP Conference

In this video interview, Andrew Blauvelt, MD, MBA, dermatologist and clinical researcher at the Oregon Medical Research Center, explains the biggest moves in psoriasis that everyone in the health care field needs to know.

In this video interview, Andrew Blauvelt, MD, MBA, dermatologist and clinical researcher at the Oregon Medical Research Center, highlights his key takeaways from his presentation at the Annual Society of Dermatology Nurse Practitioners Symposium, held April 22-23, in Nashville, Tennessee. 

Conferences (Dont Use)

NP Review: Clinical Implications of Psoriasis

In a health care industry where 75% of today’s professionals may no longer still be working in the sector by 2025, the number of nurse practitioners (NPs) is growing.

There are approximately 355,000 NPs in the United States and all are pivotal in patient care. This number is a 9% increase from 2021 and of that number, more than 5,000 are dermatology NPs.

 As Kathleen Haycraft, DNP, FNP-BC, DCNP, FAANP, a member of the board of directors, American Association of Nurse Practitioners, in Austin, Texas, noted in her presentationat the 3rd annual Society of Dermatology Nurse Practitioners (SDNP) Annual Symposium, that role will expand by 36% by 2026.

Many states have begun passing laws that give full practice authority to NPs. New York has become the 25th state to make this decision.

 Haycraft also noted that numerous studies show that states with full practice authority have better outcomes—and that statistic is unaffected by the complexity of a patient visit as shown in coding.

She then outlined strategies she would like to see NPs and the industry employ as the NP role evolves:

Nationally standardized training: “We need a national certification exam for dermatology NPs,” Haycraft said. That would, she said, strengthen NPs’ qualifications in the job market.

Improved measurements for clinical hours: “We also need to better track and measure those hours—that experience counts,” she said. “If you teach, this is something you need to assess and quantify.”

The end of rigid practice hierarchies: “Statutory team models create a team by law and set someone in charge of that team—a physician,” Haycraft said. “Organic teams develop naturally.”

As the role of the NP becomes only more important, it is imperative that there are steps taken to help strengthen their authority in dermatology patient care, Haycroft concluded.

Haycraft has served on advisory boards for BioFrontera, LEO Pharma, Ortho-Derm and UCB and has advised Regeneron.

Washington Post-KFF frontline health-care workers survey, Feb. 11-March 7, 2021. Washington Post. Updated April 22, 2022. Accessed April 22, 2022. 

https://www.washingtonpost.com/context/washington-post-kff-frontline-health-care-workers-survey-feb-11-march-7-2021/ba15a233-9495-47a9-9cdd-e7fa1578b1ca/

NP fact sheet. American Association of Nurse Practitioners. Accessed April 22, 2022. 

https://www.aanp.org/about/all-about-nps/np-fact-sheet

Haycraft K. Hot topics in dermatology. Presented at: The Society of Dermatology Nurse Practitioners Annual Symposium; April 22-23, 2022; Nashville, TN.

New York grants nurse practitioners full practice authority. Healthcare Dive. Published April 13, 2022. Accessed April 22, 2022. 

https://www.healthcaredive.com/news/new-york-nurse-practitioner-full-practice-authority-COVID/622043/

The healthcare industry is experiencing a significant shift, with a growing number of nurse practitioners (NPs) playing a crucial role in patient care. The NP workforce in the U.S. has increased by 9% since 2021, with over 5,000 specializing in dermatology. Full practice authority for NPs is expanding, with New York being the 25th state to adopt this policy, leading to improved patient outcomes. Key strategies for advancing the NP role include standardized training, better tracking of clinical hours, and the dismantling of rigid practice hierarchies to foster organic team development.

At the opening session of the Society of Dermatology Nurse Practitioners Annual Symposium, Kathleen Haycraft, DNP, FNP-BC, DCNP, FAANP, shared insights into the state of the profession and what’s ahead.

Key Insights for Dermatology Nurse Practitioners

Which factor is most important in early life development of atopic dermatitis (AD)? Could it be early antibiotic exposure, transepidermal water loss, the microbiome of the patient, or time spent in the newborn intensive care unit? Lisa Swanson, MD, a pediatric dermatologist at Ada West Dermatology and St Luke’s Children’s Hospital in Meridian, Idaho, explained during her presentation at the 2022 Society of Dermatology Nurse Practitioners Symposium that all 4 of these could factor into the development of AD but that currently there is no clear answer as to which is most important.

Swanson described how growing evidence links food allergies and AD—an association the American Academy of Dermatology recently explored

—but they might be associated differently than previously thought. It appears in recent research that the AD might actually be causing the food allergy via increased aerosolized food parti- cle exposure through the skin. In fact, a Japanese study looked at 177 infants with severe AD and found that the incidence of food allergy at age 3 was lower in infants that had their AD appropriately treated with topical steroids.

She noted many parents are asking for natural therapy options but it is difficult to make sugges- tions due to a lack of formal studies. Natural ther- apies that have been studied include the following:

olive oil, which has been shown to worsen symptoms of AD

 but more research is needed, according to Swanson;

coconut oil, has antibacterial properties but does not seem to impact the eczema itself

sunflower seed oil, which may help, but it can be difficult to find a wellprepared formula.

Swanson said AD is associated with increased risk of multiple comorbidities, including mental health issues, allergies, and cardiovascular dis- ease. Perhaps one of the most devasting issues with having AD is the lack of sleep, which both pediatric patients and parents struggle with. These sleep disturbances can even result in less growth hormone secretion. Less growth hormone often means that kids with bad AD can be low on growth curves with respect to height and weight.

“Growth hormone also plays a huge role in bone formation,” Swanson said. “So that might explain the increased osteoporosis, osteopenia, and fractures in children with AD.” Also, studies have shown that the overactivity of IL-4 may neg- atively effect brain development potentially leading to increased rates of ADHD, anxiety, depression, and autism spectrum disorder in patients with AD. This means that inhibiting IL-4 could have important benefits beyond AD, Swanson said.

She then discussed a few efficacious medications available to treat the pediatric population with AD, such as fluocinolone acetonide 0.01% (Derma-Smoothe) and the Aron regimen (30 g betamethasone valerate 0.1% cream, 24 g mupirocin cream, and 400 g Vanicream). She also touched on bleach baths. Although they have been determined to not kill 

bacteria (as was previously thought), they do still have some benefits for those with AD, which Swanson said is probably due to an anti-inflammatory effect on the skin.

According to Swanson, dupilumab (Dupix- ent; Regeneron Pharmaceuticals, Inc, and Sanofi), which is FDA approved for AD in patients 6 years and older, has changed pediatric AD treatment. The FDA has also accepted for priority review the supplemental biologics license application for dupilumab as an add-on maintenance treatment for children aged 6 months to 5 years with moder- ate to severe AD that is not adequately controlled with topical prescription therapies or for whom those therapies are not advisable.

Dupilumab is a fully human monoclonal antibody that inhibits the signaling of the IL-4 and IL-13 pathways and is not an immunosuppressant. Swanson explained that she does not do a load- ing dose for her pediatric patients. “My personal style has been to not do a loading dose in kids. It’s just too hard on them. I don’t want the first experience to be so traumatizing that they don’t come back,” she said, adding that in the Liberty AD PRESCHOOL trial (NCT03346434), there was no loading dose used in the younger age group.

The other development in AD for patients older than 12 years old includes Janus kinase (JAK) inhibitors. Swanson explained that although there is a black box warning on these JAK inhibitors because of safety concerns stemming from studies done in patients on tofacitinib (Xeljanz) with rheumatoid arthritis who were older than 50 with at least 1 cardiovascular risk factor. While this might not be representative of AD patients, the warning is still important to understand and communicate clearly to patients. It is important to monitor patients on oral JAK inhibitors with labs, skin checks, and regular appointments to assess for any issues.

For patients on oral JAK inhibitors, Swanson explained they should have a complete blood count, a comprehensive metabolic panel, and a lipid panel done at baseline, 1 month, and every 3 months after. In addition, a QuantiFERON-TB Gold test and hepatitis B and C tests should be done at baseline and, depending on the patient, annually. Also, although creatine kinase elevations were observed in past studies, they were transient and not clinically relevant, so in her opinion, there is no need to test a patient for them.

With the oral JAK inhibitors, it is important to consider baseline liver and kidney function and patients must be advised to avoid live vaccines, pregnancy and breastfeeding. “Consider talking about [herpes simplex virus] suppression if a patient has a history of cold sores and consider the Zoster vaccination if they’re old enough to qualify for it,” Swanson said.

Swanson is a speaker for Sanofi-Regeneron, Pfizer, Incyte, Lilly, Janssen, Ortho Dermatologics and Novartis. She has served on advisory boards for Janssen,Lilly, and Sanofi-Regeneron.

Swanson E. Updates in pediatric dermatology. Presented at: The Society of Dermatology Nurse Practitioners Annual Symposium; April 22-23, 2022; Nashville, TN.

Davis DMR, Drucker AM, Alikhan A, et al. AAD Guidelines: awareness of comorbidities associated with atopic dermatitis in adults. Journal of the American Academy of Dermatology. Published online January 2022:S0190962222000809. doi: 10.1016/j.jaad.2022.01.009.

Miyaji Y, Yang L, Yamamoto-Hanada K, Narita M, Saito H, Ohya Y. Earlier aggressive treatment to shorten the duration of eczema in infants resulted in fewer food allergies at 2 years of age. The Journal of Allergy and Clinical Immunology: In Practice. 2020;8(5):1721-1724.e6. doi:10.1016/j.jaip.2019.11.036

Danby SG, AlEnezi T, Sultan A, et al. Effect of olive and sunflower seed oil on the adult skin barrier: implications for neonatal skin care. Pediatr Dermatol.2013;30(1):42-50. doi:10.1111/j.1525-1470.2012.01865.x

Get the facts about CBD and eczema. National Eczema Association. Published June 18, 2020. Accessed April 22, 2022. 

https://nationaleczema.org/get-the-facts-cbd/

Will coconut oil help your eczema? National Eczema Association. Published November 19, 2018. Accessed April 22, 2022. 

https://nationaleczema.org/get-the-facts-coconut-oil/

FDA accepts dupixent (dupilumab) for priority review in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis. Regeneron Pharmaceuticals Inc. Press release. Published February 10, 2022. Accessed April 22, 2022. https://investor.regeneron.com/news-releases/news-release-details/fda-accepts-dupixentr-dupilumab-priority-review-children-aged-6/

Atopic dermatitis (AD) development in early life may be influenced by factors such as antibiotic exposure, transepidermal water loss, microbiome, and NICU time, but no definitive cause is identified. AD is linked to food allergies, potentially due to increased skin exposure to food particles. Treatment with topical steroids can reduce food allergy incidence. Natural therapies lack formal studies, and AD is associated with comorbidities like mental health issues and cardiovascular disease. Dupilumab and JAK inhibitors are promising treatments, with specific monitoring and safety considerations for pediatric patients.

In her presentation at the 3rd Annual Society of Dermatology Nurse Practitioners Symposium, Lisa Swanson, MD, discussed the important updates in pediatric dermatology, including early life interventions, food allergies, and more. 

Rocco Serrao, MD

Articles

Latest Updated Articles